Inhibikase Therapeutics (IKT) FCF Margin (2020 - 2023)
Historic FCF Margin for Inhibikase Therapeutics (IKT) over the last 4 years, with Q4 2023 value amounting to 344243100.0%.
- Inhibikase Therapeutics' FCF Margin fell 3442375052300.0% to 344243100.0% in Q4 2023 from the same period last year, while for Sep 2024 it was 1724492300.0%, marking a year-over-year decrease of 17244866841700.0%. This contributed to the annual value of 6947.87% for FY2023, which is 73054900.0% up from last year.
- Latest data reveals that Inhibikase Therapeutics reported FCF Margin of 344243100.0% as of Q4 2023, which was down 3442375052300.0% from 5159.16% recorded in Q3 2023.
- In the past 5 years, Inhibikase Therapeutics' FCF Margin ranged from a high of 200.41% in Q3 2020 and a low of 344243100.0% during Q4 2023
- Over the past 4 years, Inhibikase Therapeutics' median FCF Margin value was 4540.49% (recorded in 2023), while the average stood at 21539540.75%.
- Per our database at Business Quant, Inhibikase Therapeutics' FCF Margin soared by 2000000000bps in 2022 and then crashed by 2000000000bps in 2023.
- Quarter analysis of 4 years shows Inhibikase Therapeutics' FCF Margin stood at 555.42% in 2020, then crashed by -37833bps to 210690.17% in 2021, then surged by 97bps to 5594.77% in 2022, then crashed by -6152840bps to 344243100.0% in 2023.
- Its last three reported values are 344243100.0% in Q4 2023, 5159.16% for Q3 2023, and 3921.82% during Q2 2023.